Suicide gene therapy

Principles of Molecular Oncology: Third Edition

Volumn , Issue , 2008, Pages 367-382

  Schepelmann, Silke ^a   Niculescu Duvaz, Ion ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82055206003     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-470-4_18     Document Type: Chapter

References (201)

1. Bridgewater G, Springer CJ, Knox R, Minton N, Michael P, Collins M. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur J Cancer 1995;31A:2362-2370.
2. Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Genedirected enzyme prodrug therapy with a mustard prodrug/ carboxypeptidase G2 combination. Cancer Res. 1996;56:4735-4742.
3. Eaton JL, Perry MJA, Todryk SM, et al. Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques. Gene Therap. 2001;8:557-567.
4. Huber BE, Richards CA, Austin EA. VDEPT; An enzyme/ prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv Drug Delivery Rev. 1995;17:279-292.
5. Hermiston T. Gene-delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest. 2000;105:1169-1172.
6. Green NK, Seymour LW. Adenoviral vectors: Systemic delivery and tumor targeting. Cancer Gene Therap. 2002;9:1036-1042.
7. Ponnazhagan S, Curiel DT, Shaw DR., Alvarez RD, Siegal GP. Adeno-associated virus for cancer gene therapy. Cancer Res. 2001;61:6313-6321.
8. Glorioso JC, De Luca NA, Fink DJ. Development and application of herpes simplex virus vector for gene therapy. Annu Rev Microbiol. 1995;49:675-710.
9. Su H, Lu R, Ding R, Kan YW. Adeno-associated viral-mediated gene transfer to hepatoma: Thymidine kinase/interleukin 2 is more effective in tumor killing in non-ganciclovir (GCV)-treated animals. Mol Ther. 2000;1:509-515.
10. Gerolami R, Uch R, Faivre J, et al. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol. 2004;40:291-297.
11. Schoensiegel F, Paschen A, Sieger S, et al. MIA (melanoma inhibitory activity) promoter-mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther. 2004;11:408-418.
12. Shen Y, Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther. 2006;11:975-992
13. Klatzmann D, Valery CA, Bensimon G, et al. A phase I/II study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for recurrent glioblastoma. Study Group on Gene Therapy for Glioblastoma. Hum Gene Ther. 1998;9:2595-2604.
14. Solly SK, Trajcevski S, Frisen C, et al. Replicative retroviral vectors for cancer gene therapy. Cancer Gene Ther. 2003:10:30-39.
15. Braybrooke JP, Slade A, Deplanque G, et al. Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma. Clin Cancer Res. 2005;11:1512-1520.
16. Fernandez M, Porosnicu M, Markovic D, Barber GN. Genetically engineered vesicular stomatitis virus in gene therapy: Application for treatment of malignant disease. J Virol. 2002;76:895-904.
17. Tseng JC, Zanzonico PB, Levin B, et al. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med. 2006;47:1136-1143.
18. Gnant MF, Puhlmann M, Alexander HR, Bartlett DL. Systematic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 1999;59:3396-3403.
19. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther. 1999;10:649-657.
20. Spooner RA, Deonarain MP, Epenetos AA. DNA vaccination for cancer treatment. Gene Ther. 1995;2:173-180.
21. Soghomonyan SA, Doubrovin M, Pike J, et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 2005;12:101-108.
22. Miller AD. Cationic liposomes for gene therapy. Angewandte Chem Internatl Ed. 1998;37:1768-1785.
23. Schatzlein AG. Non-viral vectors in cancer gene therapy: Principles and progress. Anti-Cancer Drug Design. 2001;12:275-304.
24. Ilies MA, Seitz MA, Balaban AT. Cationic lipids in gene delivery: Principles, vector design and therapeutical application. Curr Pharmaceut Design. 2002;8:2441-2474.
25. Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving highdose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res. 2005;11:7444-7453.
26. Immonen A, Vapalahti M, Tyynela K, et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomized, controlled study. Mol Ther. 2004;10:967-972.
27. Chevez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirusmediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol. 2005;23:7927-7935.
28. Morris JC, Ramsey WJ, Wildner O, et al. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (Adv.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma. Hum Gene Ther. 2000;11:487-503.
29. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the E coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997;8:985-1001.
30. Sung MW, Yeh HC, Thung SN, et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: Results of a phase I clinical trial. Mol Ther. 2001;4:182-191.
31. Hasenburg A, Tong XW, Fischer DC, et al. Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up. Gynecol Oncol. 2001;83:549-554.
32. Kubo H, Gardner TA, Wada Y, et al. Phase I dose escalation clinical trial of adenovirus vector carrying osteocalcin promoterdriven herpes simplex virus thymidine kinase in localized and metastatic hormone-refractory prostate cancer. Hum Gene Ther. 2003;14:227-241.
33. Ezzeddine ZD, Martuza RL. Platika D, et al. Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene. New Biol. 1991;3:608-614.
34. Barba D, Hardin J, Ray J, Gage FH. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg. 1993;79:729-735.
35. Sandmair AM, Loimas S, Puranen P, et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther. 2000;11:2197-2205.
36. Mavria G, Porter CD. Reduced growth in response to ganciclovir treatment of subcutaneous xenografts expressing HSV-tk in the vascular compartment. Gene Ther. 2001;8:913-920.
37. Barzon L, Bonaguro R, Castagliuolo I, et al. Transcriptionally targeted retroviral vector for combined suicide and immunomodulating gene therapy of thyroid cancer. J Clin Endocrinol Metab. 2002;87:5304-5311.
38. Kan O, Griffiths L, Baban D, et al. Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer. Cancer Gene Ther. 2001;8:473-482.
39. Humphreys MJ, Ghaneh P, Greenhalf W, et al. Hepatic intraarterial delivery of a retroviral vector expressing the cytosine deaminase gene, controlled by the CEA promoter and intraperitoneal treatment with 5-fluorocytosine suppresses growth of colorectal liver metastases. Gene Ther. 2001;8:1241-1247.
40. Shand N, Weber F, Mariani L, et al. A phase 1-2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir. Hum Gene Ther. 1999;10:2325-2335.
41. Rados MD, McDermott M, Chang SM, et al. Treatment of progressive or recurrent glioblastoma multiforme in adults with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration: A phase I/II multi-institutional trial. J Neurooncol. 2003;65:269-278.
42. Rainov NG. A phase III clinical evaluation of herpes simplex virus type I thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther. 2000;11:2389-2401.
43. Miyatake S, Martuza RL, Rabkin SD. Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther. 1997;4:222-228.
44. Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001;8:332-339.
45. Moriuchi S, Wolfe D, Tamura M, et al, Double suicide gene therapy using a replication defective herpes simplex virus vector reveals reciprocal interference in a malignant glioma model. Gene Ther. 2002;9:584-591.
46. Moriuchi S, Glorioso JC, Maruno M, et al. Combination gene therapy for glioblastoma involving herpes simplex virus vectormediated codelivery of mutant IkappaBalpha and HSV thymidine kinase. Cancer Gene Ther. 2005;12:487-496.
47. Martuza RL. Conditionally replicating herpes vector for gene therapy. J Clin Invest. 2000;105:841-846.
48. Curiel DT, Gerritsen WR, Krul MR. Progress in cancer gene therapy. Cancer Gene Therapy. 2000;7:197-1199.
49. Heise C, Kirn HD. Replication-selective adenoviruses as oncolytic agents. J Clin Investig. 2000;105:847-851.
50. Hermiston TV, Kuhn I. Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Therap. 2002;9:1022-1035.
51. Ichikawa T, Chiocca EA. Comparative analyses of transgene delivery and expression in tumors inoculated with a replicationconditional or-defective viral vector. Cancer Res. 2001;61:5336-5339.
52. Kirn D. Replication-selective oncolytic adenoviruses: Virotherapy aimed at genetic targets in cancer. Oncogene. 2000;19:6660-6669.
53. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a generically engineered virus mutant. Sci. 1991;252:854-856.
54. Herminston T. Khun I. Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes. Cancer Gene Therap. 2002;9:1022-1035.
55. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med. 2001;7:781-787.
56. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207, for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 2000;7:867-874.
57. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. Cancer Res. 1999;59: 410-413.
58. Wildner O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virustk: Assessment of antitumor efficacy and toxicity. Cancer Res. 2000;60:4167-4174.
59. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. Caner Res. 2001;61:8743-8750.
60. Morris JC, Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tK. Mol Ther. 2000;1:56-62.
61. Wildner O, Morris JC. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. J Gene Med. 2000;2:353-360.
62. Lambright ES, Amin K, Wiewrodt R, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. Gene Ther. 2001;8:946-953.
63. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther. 2004;4:41-51.
64. Zhan J, Gao Y, Wang W, et al. Tumor-specific intravenous gene delivery using oncolytic adenoviruses. Cancer Gene Ther. 2005;12:19-25.
65. Liu Y, Deisseroth A. Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy. Cancer Gen Ther. 2006;13:845-855.
66. Chen MJ, Green NK, Reynolds GM, et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. Gene Ther. 2004;11:1126-1136.
67. Lukashev AN, Fuerer C, Chen MJ, Searle P, Iggo R. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. Hum Gene Ther. 2005;16:1473-1483.
68. Schepelmann S, Hallenbeck P, Ogilvie LM, et al. Systemic genedirected enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res. 2005;65:5003-5008.
69. Stubdal H, Perin N, Lemmon M, et al. A prodrug strategy using ONYX-0150-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res. 2003;63:6900-6908.
70. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy. Human Gene Therap. 1998;9:1323-1333.
71. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenvovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62:4968-4976.
72. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 2002;62:3812-3818.
73. Krasnykh V, Dmitriev I, Navarro J-G, et al. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 2000;60:6784-6787.
74. Liu Y, Ye T, Maynard J, Akbulut H, Deisseroth A. Engineering conditionally replication-competent adenoviral vectors carrying the cytosine deaminase gene increase the infectivity and therapeutic effect for breast cancer gene therapy. Cancer Gene Ther. 2006;13:346-356.
75. Kitazono M, Goldsmith ME, Aikou T, Bates S, Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res. 2001;61:6328-6330.
76. Anders M, Christian C, McMahon M, McCormick F, Korn WM. Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res. 2003;63:2088-2095.
77. Boviatsis EJ, Park JS, Sena-Esteves M, et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 1994;54:5745-5751.
78. Nakamura H, Mullen JT, Chanrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replicationconditional herpes simplex virus 1 mutant that express yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine tom 5-fluorouracil. Cancer Res. 2001;61:5447-5452.
79. Pawlik TM, Nakamura H, Mullen JT, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus I mutant that expresses the CYP2B1 transgene. Cancer. 2002;95:1171-1181.
80. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca IA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res. 1999;59:3861-3865.
81. Tyminski E, LeRoy S, Terada K, et al. (2005) Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. Cancer Res. 2005;65:6850-6857.
82. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res. 2002;62:6089-6098.
83. Porosnicu M, Mian A, Barber GN. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphorbiosylltransferase suicide gene. Cancer Res. 2003;63:8366-8376.
84. Gnant MF, Berger AC, Huang J, et al. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumorspecific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus. Cancer Res. 1999;59:4668-4674.
85. Kirn D. Replication-selective microbiological agents: Fighting cancer with targeted germ warfare. J Clin Invest. 2000;105:837-839.
86. Pawelek JM, Low KB, Bermudes D. Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 1997;57:4537-4544.
87. Tjuvaev J, Blasberg R, Luo X, Zheng LM, King I, Bermudes D. Salmonella-based tumor-targeted cancer therapy: Tumor amplified protein expression therapy (TAPET) for diagnostic imaging. J Control Release. 2001;74:313-315.
88. Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S. Bifidobacterium longum as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors. Cancer Gene Ther. 2000;7:269-274
89. Nuyts S, Theys J, Landuyt W, Van Mellaert L, Lambin P, Anne J. Increasing specificity of anti-tumour therapy: Cytotoxic proteins delivery by non-pathogenic Clostridia under regulation of radioinduced promoter. Anticancer Res. 2001;21:857-862.
90. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Lambin P, Anne J. The use of radiation-induced bacterial promoters in anaerobicconditions: A means to control gene expression in Clostridiummediated gene therapy. Radiation Res. 2001;155:716-723.
91. Liu S-C, Minton NP, Giaccia AJ, Brown JM. Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis. Gene Therap. 2002;9:291-296.
92. Luo D, Salzman WM. Synthetic DNA delivery systems. Nature Biotech. 2000;18:33-37.
93. Djeha AH, Hulme A, Dexter MT, et al. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of CB1954. Cancer Gene Ther. 2000;7:721-731.
94. Lohr F, Lo DY, Zaharoff DA, et al. Effective tumor therapy with plasmid cytokines combined with in vivo electroporation. Cancer Res. 2001;61:3281-3284.
95. Bentires-Alj M, Helin A-C, Lechanteur C, et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther. 2000;7:20-26.
96. Harada Y, Iwai M, Tanaka S, et al. Highly efficient suicide gene expression in hepatocellular carcinoma cells by Epstein-Barr virus-based plasmid vectors combined with polyamidoamine dendrimer. Cancer Gene Ther. 2000;7:27-36.
97. Kanyama H, Tomita N, Yamano T, et al. Usefulness of repeated intratumoral gene transfer using hemagglutinating virus of Japan-liposome method for cytosine deaminase suicide gene therapy. Cancer Res. 2001;61:14-18, 100.
98. Hagihara Y, Saitoh Y, Kaneda Y, Kohmura E, Yoshimine T. Widespread gene transfection into the central nervous system of primates. Gene Ther. 2000;7:759-763.
99. Mc Kay TR, MacVinish LJ, Carpenter B, et al. Selective in vivo transfection of murine biliary epithelia using polycationenhanced adenovirus. Gene Ther. 2000;7:644-652.
100. Xu L, Pirollo KF, Rait A, Murray AL, Chang EH. Systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Targeting. 1999;4:92-104.
101. Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ. Targeting gene therapy for cancer. Oncol Res. 1997;9:313-325.
102. Hayes GM, Carpenito C, Davis PD, Dougherty ST, Dirks GF, Dougherty GH. Alternative splicing as a novel means of regulating the expression of therapeutic genes. Cancer Gene Ther. 2002;9:133-141.
103. De Fatta RJ, Li Y, De Benedetti A. Selective killing of cancer cells based on translational control of suicide gene therapy. Cancer Gene Ther. 2002;9:573-578.
104. De Fatta RJ, Chervenack RP, De Benedetti A. A cancer gene therapy approach through translational control of a suicide gene. Cancer Gene Ther. 2002;9:502-505.
105. Kirn D. Clinical research results with dI 1520 (ONYX-015), a replication selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 2001;8:89-98.
106. Spear MA. Gene therapy of gliomas: Receptors and transcriptional targeting. Anticancer Research. 1998;18:3223-3232.
107. Gerolami R, Cardoso J, Lewin M, et al. Evaluation of HSV-tk gene therapy in rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res. 2000;60:993-1001.
108. Kurihara T, Brough DE, Kovesti I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC-1 antigen. J Clin Invest. 2000;106:763-771.
109. Siders WM, Halloran PJ, Fenton RG. Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus. Cancer Gene Ther. 1998;5:281-291.
110. Koshikawa N, Takenaga K, Tagawa M, Sakiyama S. Therapeutic efficacy of the suicide gene driven the promoter of vascular endothelial growth factor gene against hypoxic tumor cells. Cancer Res. 2000;60:2936-2941.
111. Latham JPF, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue specific adenovirus vector. Cancer Res. 2000;60:334-341.
112. Ido A, Uto H, Moriuchi A, et al. Gene therapy targeting for hepatocellular carcinoma: Selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human a-fetoprotein promoter. Cancer Res. 2001;61:3016-3021.
113. Peng XY, Won JH, Rutherford T, et al. The use of L-plastin promoter for adenoviral-mediated , tumor-specific gene-expression in ovarian and bladder cancer cell lines. Cancer Res. 2001;61:4405-4413.
114. Scarpini CG, May J, Lachman RH, et al. Latency associated promoter transgene expression in the central nervous system after stereotaxic delivery of replication-defective HSV-1-based vectors. Gene Ther. 2001;8:1057-1071.
115. Nishino K, Osaki T, Kumagai T, et al. Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a myc-max binding motif. Internatl J Cancer. 2001;91:851-856.
116. Ueda K, Iwahashi M, Nakamori M, et al. Carcinoembryonic antigen-specific suicide gene therapy of cytosine deaminase/ 5-fluoro-cytosine enhanced by the Cre/loxP system in the orthotopic gastric carcinoma model. Cancer Res. 2001;61:6158-6162.
117. Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 2001;61:6012-6019.
118. Springer CJ, Niculescu-Duvaz I. Gene-directed enzyme prodrug therapy. IN: Anticancer Drug Development (ed. B Baguley), 2001; pp 137-135. Academic Press., San-Diego.
119. Yoon KJ, Qi J, Remack JS, et al. Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. Mol Cancer Ther. 2006;5:1577-1584.
120. Trudeau C, Yuan S, Galipeau J, Benlimame N, Alaoui-Jamali MA, Batist G. A novel parasite-derived suicide gene for cancer gene therapy with specificity for lung cancer cells. Human Gene Ther. 2001;12:1673-1680.
121. Greco O, Folkes LK, Wardman P, Tozer GM, Dachs GU. Development of a novel enzyme/prodrug combination for gene therapy of cancer: Horseradish peroxidase/indole-3-acetic acid. Cancer Gene Ther. 2000;7:1414-1420.
122. Tupper J, Greco O, Tozer GM, Dachs GU. Analysis of the horseradish peroxidase/indole-3-acetic acid combination in a threedimensional tumor model. Cancer Gene Ther. 2004;11:508-513.
123. Simonova M, Wall A, Weissleder R, Bogdanov A. Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells. Cancer Res. 2000;60:6656-6662.
124. Cortes ML, de Felipe P, Martin V, Hughes MA, Izquierdo M. Successful use of a plant gene in the treatment of cancer in vivo. Gene Ther. 1998;5:1499-1507.
125. Aghi M, Hochberg F, Breakfield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2000;2:148-164.
126. Yakkundi A, McErlane V, Murray M, et al. Tumor-selective drug activation: A GDEPT approach utilizing cytochromeP450 1A1 and AQ4N. Cancer Gene Ther. 2006;13:598-605.
127. Potter GA, Patterson LH, Wanogho E. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by cytochrome P450 enzyme 1B1. Br J Cancer. 2002;86:774-778.
128. McFadyen MCE, Melvin WT, Murray GI. Cytochrome P450 enzymes: Novel options for cancer therapeutics. Mol Cancer Ther. 2004;3:363-371.
129. Savage P, Cowburn P, Clemen D, et al. Suicide gene therapy: Conversion of ethanol to acetaldehyde mediated by human beta 2 alcohol dehydrogenase. Cancer Gene Ther. 2004;11:774-781.
130. Spooner RA, Maycroft KA, Paterson H, Friedlos F, Springer CJ, Marais R. Appropriate subcellular location of prodrugactivating enzymes has important consequences for suicide gene therapy. Internatl J Cancer. 2001;93:123-130.
131. Hamstra DA, Page M, Maybaum J, Rehemtulla A. Expression of endogenously activated secreted or cell surface carboxypeptidase A sensitizes tumor cells to methotrexate-a-peptide prodrugs. Cancer Res. 2000;60:657-665.
132. Heine D, Muller R, Brusselbach S. Cell surface display of a lysosomal enzyme for extra-cellular gene-directed enzyme prodrug therapy. Gene Ther. 2001;8:1005-1010.
133. Marais R, Spooner RA, Stribbling SM, Light Y, Martin J, Springer CJ. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotech. 1997;15:1373-1377.
134. Weyel D, Sedlacek HH, Muller R, Brusselbach S. Secreted human β-glucuronidase: A novel tool for gene-directed enzyme prodrug therapy. Gene Ther. 2000;7:224-231.
135. Potter PM, Pawlick CA, Morton CL, Naeve CV, Danks MK. Isolation and partial characterization of a cDNA encoding rabbit liver carboxyl esterase that activates the prodrug irinotecan (CPT-11). Cancer Res. 1998;58:2646-2651.
136. Wierdl M, Morton CL, Weeks JK, Danks MK, Harris LC, Potter PM. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res. 2001;61:5078-5082.
137. Jounaidi Y, Chen C-S, Veal GJ, Waxman DJ. Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydrxylase P450 2B11. Mol Cancer Ther. 2006;5:541-555.
138. Kokoris MS, Black ME. Characterization of herpes simplex virus type 1 kinase mutants engineered for improved ganciclovir and acyclovir activity. Protein Sci. 2002;11:2267-2272.
139. Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 1995;2:702-709.
140. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cellular Physiol. 2001;187:22-36.
141. Niculescu-Duvaz I, Spooner R, Marais R, Springer CJ. Genedirected enzyme prodrug therapy. Bioconjug Chem. 1998;9:4-22.
142. Denny WA. Prodrugs for gene-directed enzyme prodrug therapy (GDEPT). Biomed Biotechnol. 2003;1:48-70.
143. Tercel M, Denny WA, Wilson WR. A novel nitro-substituted seco-Cl: Application as a reductively activated ADEPT prodrug. Bioorg Med Chem Let. 1996;6:2741-2744.
144. Chen L, Waxman DJ, Chen D, Kufe DC. Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P-450 gene. Cancer Res. 1996;56:1331-1340.
145. Kojima A, Hackett NR, Ohwada A, Crystal RG. In vivo human carboxylesterase cDNA gene transfer to activate the prodrug CPT-11 for local treatment of solid tumors. J Clin Invest. 1998;101:1789-1796.
146. Springer CJ, Niculescu-Duvaz I. Prodrug-activating systems in suicide gene therapy. J Clin Invest. 2000;105:1161-1167.
147. Degreve B. De Clerq E, Balzarini J. Bystander effect of purine nucleoside analogues in HSV-tk suicide gene therapy is superior to that of pyrimidine nucleoside analogues. Gene Ther. 1999;6:162-170.
148. Farquhar D, Cherif A, Bakina E, Nelson GA. Intensely potent doxorubicin analgoues: Structure-activity relationships. J Med Chem. 1998;41:965-972.
149. Griffiths L, Binley K, Iqball S, et al. The macrophage-a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 2000;7:255-262.
150. McCart JA, Puhlmann M, Lee J, et al. Complex interaction between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther. 2000;7:1217-1223.
151. Denny WA, Wilson WR. The design of selectively-activated anti-cancer prodrugs for use in antibody-directed and genedirected enzyme prodrugs therapies. J Pharmaceut Pharmacol. 1998;50:387-394.
152. Niculescu-Duvaz I, Baracu I, Balaban AT. (1990). Alkylating agents. In Chemistry of Antitumour Agents (ed. DEV Wilman), pp. 63-131. Blackie, London.
153. Secrist JA, Parker WB, Allan PW, et al. Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides. 1999;18:745-757.
154. Denny WA. The design of selectively-activated prodrugs for cancer chemotherapy. Curr Pharma Design. 1996;2:281-294.
155. Tietze L, Hanemann R, Buhr W, Logers M, Menningem P. Prodrugs of the cytostatic CC-1065 that can be activated in a tumor selective manner. Angewante Chemie International Edition. 1996;35:2674-2677.
156. Tietze LF, Feuerstein T, Feher A, Haunbert F, Pranknin O. Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: The development of highly potent prodrugs. Angewante Chemie International Edition. 2003;41:759-761.
157. Springer CJ, Niculescu-Duvaz I, Mauger AB, et al. The design of prodrugs for antibody directed enzyme prodrug therapy. IN: R Begent and A Hamlin, editors; New Antibody Technology and Emergence of Useful Cancer Therapy. 1995; London, The Royal Society of Medicine Press; 75-79.
158. Nakamuro K, Okuno T, Hasegawa T. Metabolism of selenoamino acids and contribution of selenium methylation to their toxicity. J Health Sci. 2000;46:418-421.
159. Wolf CR, Statham CN, McMenamin MG, Bend JR, Boyd MR, Philpot RM. The relationship between the catalytic activities of rabbit pulmonary cytochrome P-450 isozymes and the lungspecific toxicity of the furan derivative, 4-ipomeanol. Molecular Pharmacol. 1982;22:738-744.
160. Ellard S, Parry JM. A comparative study of the use of primary Chinese-hamster liver cultures and genetically-engineered immortal V79 Chinese-hamster cell-lines expressing rat liver CYP1A1, 1A2 and 2B1 cDNAs in micronucleus assays. Toxicol. 1993;82:131-149.
161. Friedlos F, Denny WA, Palmer BD, Springer CJ. Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. J Med Chem. 1997;40:1270-1275.
162. Asche C, Dumy P, Carrez D, Croisy A, Demeunynk M. Nitrobenzylcarbamate prodrugs of cytotoxic acridines for potential use with nitroreductase gene-directed enzyme prodrug therapy. Bioorg Med Chem Lett. 2006;1990-1994.
163. Jiang Y, Han J, Yu C, et al. Design, synthesis and biological evaluation of cyclic and acyclic nitrobenzylphophoramide mustards for E. coli nitroreductase activation. J Med Chem. 2006;49:4333-4343.
164. Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos,F, et al. Selfimmolative anthracycline prodrugs for suicide gene therapy. J Med Chem. 1999;42:2485-2489.
165. Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos F. Niculescu-Duvaz I, Niculescu-Duvaz D, Friedlos,F, et al. Self-immolative anthracycline prodrugs for suicide gene therapy. J Med Chem. 1999;42:2485-2489.
166. Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, et al. Selfimmolative nitrogen mustards prodrugs cleavable by carboxypeptidase Ge (CPG2) showing large cytotoxicity differential in GDEPT. J Med Chem. 2003;46:1690-1705.
167. Niculescu-Duvaz I, Scanlon I, Niculescu-Duvaz D, et al. Significant differences in biological parameters between prodrugs cleavable by carbozypeptidase G2 that generate 3,5-diflurophenol and aniline mustards in gene-directed enzyme prodrug therapy. J Med Chem. 2004:47-2651-2658.
168. Davies LC, Friedlos F, Hedley D, et al. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. J Med Chem. 2005;48:5321-5328.
169. Ghosh AK, Khan S, Marini F, Nelson JA, Farquhar D. A daunorubicin b-galactoside prodrug for use in conjunction with gene-directed enzyme prodrug therapy. Tetrahedron Lett. 2000;41:4871-4874.
170. McMasters RA, Wilbert TN, Jones KE, et al. Two-drug combinations that increase apoptosis and modulate Bak and Bcl-Xl expression in human colon tumor cell lines transduced with herpes simplex virus thymidine kinase. Cancer Gene Ther. 2000;7:563-573.
171. Boucher PD, Ostruszka LJ, Murphy PJM, Shewach DS. Hydroxyurea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Ther. 2002;9:1023-1030.
172. Huang Z, Waxman DJ. Modulation of cyclophosphamide-based cytochrome p450 gene therapy using liver P450 inhibitors. Cancer Gene Ther. 2001;8:450-458.
173. Jounaidi Y, Waxman DJ. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 2000;60:3761-3769.
174. Wang D, Ruan H, Hu L, et al. Development of hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther. 2005;12:276-283.
175. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. Human Gene Ther. 2000;11:67-76.
176. Erbs P, Regulier E, Kintz J, et al. In vivo cancer gene therapy by adenovirus-mediated transfer of a bifunctional yeast cytosine deaminase/uracil phosporibosyltransgerase fusion gene. Cancer Res. 2000;60:3813-3822.
177. Shimizu T, Shimada H, Ochiai T, Hamada H. Enhanced growth suppression in esophageal carcinoma cells using adenovirusmediated fusion gene transfer uracil phosphoryl transferase and herpes simplex virus thymidine kinase. Cancer Gene Ther. 2001;8:512-521.
178. Chen SH, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival. Cancer Res. 1996;56:3758-3762.
179. Toda M, Martuza RL, Rabkin SD. Combination suicide/cytokine gene therapy gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine. Gene Ther. 2001;8:332-339.
180. Zhang J-H, Wan M-X, Pan B-R, Yu B. (2006) Cytotoxicity of HSVtk and hrTNF-a fusion genes with IRES in treatment of gastric cancer. Cancer Lett. 2006;235:191-201.
181. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proceed Natl Acad Sci USA. 1994;91:8302-8306.
182. Mesnil M, Yamasachi H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communications. Cancer Res. 2000;60:3989-3999.
183. Imaizumi K, Hasegawa Y, Kawabe T, et al. Bystander tumoricidal effect and gap junctional communication in lung cancer cells. Am J Respir Cell Mol Biol. 1998;18:205-212.
184. Andrade-Rosental AF, Rosental R, Hopperstad MD, et al. Gap junctions: The "kiss of death" and the "kiss of life". Brain Res Rev. 2000;32:308-315.
185. Wygoda MR, Wilson MR, Davis MA, Trosko JE, Rehemtulla A, Lawrence TS. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells: The Good Samaritan effect. Cancer Res. 1997;57:1699-1703.
186. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM. The bystander effect in the HSVtk/ganciclovir system and its relation to gap junctional communication. Gene Ther. 1998;5:1705-1711.
187. Touraine RL, Vahanian N, Ramsey WJ, Blaese RM. Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions. Human Gene Ther. 1998;9:2385-2391.
188. Grignet-Debrus C, Cool V, Baudson N, Velu T, Calberg-Bacq C-M. The role of cellular-and prodrug-associated factors in the bystander effect induced by the Varicella zoster and Herpes simplex viral thymidine kinases in suicide gene therapy. Cancer Gene Ther. 2000:7:1456-1468.
189. Grignet-Debrus C, Cool V, Baudson N, et al. Comparative in vitro and in vivo cytotoxic activity of BVaraU against tumor cells expressing either the Varicella zoster or the Herpes simplex virus thymidine kinase. Cancer Gene Ther. 2000;7:215-223.
190. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the "bystander effect": A cytokine cascade. Exp Hematol. 1996;24:829-838.
191. Agard C, Ligeza C, Dupas B, et al. Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis. Cancer Gene Ther. 2001;8:128-136.
192. Jones RK, Pope IM, Kinsella AR, Watson AJM, Christmas SE. Combined suicide and granulocyte-macrophage colonystimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther. 2000;7:1519-1528.
193. Majumdar A, Zolotorev A, Samuel S, et al. Efficacy of herpes simplex virus thymidine kinase in combination with cytokine gene therapy in an experimental metastatic breast cancer model. Cancer Gene Ther. 2000;7:1086-1099.
194. Cao X, Huang X, Ju DW, Zhang WP, Hamada H, Wang J. Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte macrophage colony-stimulating factor gene transfer. Cancer Gene Ther. 2000;7:177-186.
195. Rivas C, Chandler P, Melo JV, Simpson E, Apperley JF. Absence of in vitro or in vivo bystander effects in a thymidine kinase-transduced murine T-lymphoma. Cancer Gene Ther. 2000;7:954-962.
196. Karle P, Renner M, Salmons B, Gunzburg WH. Necrotic, rather than apoptotic death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther. 2001;8:220-230.
197. Stoff-Khalili MA, Dall P, Curiel DT. Gene therapy for the carcinoma of the breast. Cancer Gene Ther. 2006;13: 633-647.
198. Cutter JL, Kurozumi K, Chiocca EA, Kaur B. Gene therapeutics: The future of brain tumor therapy? Expert Rev Anticancer Ther. 2006;6:1053-1064.
199. Brooks RA, Mutch D. Gene therapy in gynecological cancer. Expert Rev Anticancer Ther. 2006;6:1013-1032.
200. Lohr M. Gene therapy for gastrointestinal tumors. Zeitschrift Gastro. 2006;44:333-340.
201. Barzon L, Zanusso M, Columbo F, Palu G. (2006) Clinical trials of gene therapy, virotherapy, and immunotherapy for malignant tumors. Cancer Gene Ther. 2006;13: 539-554.